NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
This grant will provide access to TOPMed resources for researchers to generate and share large-scale genetic and multi-omics data to study the molecular mechanisms of heart, lung, blood, and sleep disorders.
Funder: National Institutes of Health (NIH)
Due Dates: November 6, 2025 | February 6, 2026 | June 8, 2026 | October 6, 2026 | February 8, 2027 | June 8, 2027 | October 6, 2027 | February 7, 2028 | May 8, 2028 (final deadline)
Funding Amounts: No direct funding provided; access to NHLBI TOPMed omics data generation resources for up to 3 years.
Summary: Provides access to NHLBI-funded TOPMed omics capacity for generating large-scale multi-omics data to advance research on heart, lung, blood, and sleep disorders.
Key Information: No monetary award; resource access only. All data generated must be shared in public NIH-controlled-access repositories.
Description
This opportunity provides researchers with access to the National Heart, Lung, and Blood Institute (NHLBI) TransOmics for Precision Medicine (TOPMed) program's resources for generating large-scale, integrated genetic and multi-omics data. The aim is to facilitate discovery of molecular mechanisms underlying heart, lung, blood, and sleep (HLBS) disorders. No funding is awarded; instead, successful applicants receive omics assay services (e.g., whole genome sequencing, RNA-seq, methylome, metabolome, proteome, single-cell omics) performed at NHLBI-designated centers. Generated data and associated phenotypes must be deposited in NIH-controlled-access databases, such as dbGaP and BioData Catalyst, for broad scientific use.
The program is designed to move from cataloguing genetic associations to understanding mechanisms, supporting projects that leverage existing, well-phenotyped biospecimens. There is particular interest in studies addressing knowledge gaps in both common and rare HLBS diseases and in proposals that complement existing TOPMed datasets. Participation in the TOPMed consortium and data sharing are required.
